Skip to content
EntityQ120468350· pop 9· linked from 233 articles

retatrutide

Sign in to save

Also known as LY3437943, LY-3437943

Retatrutide (LY-3437943) is an experimental drug for obesity developed by the American pharmaceutical company Eli Lilly and Company. It is a triple glucagon hormone receptor agonist (GLP-1, GIP, and GCGR receptors).

Chemical data

Drug data · ChEMBL

Max clinical phase
Phase 3
Molecule type
Protein
Indications
diabetes mellitus, obesity, Renal insufficiency, type 2 diabetes mellitus

via ChEMBL · EBI

Described at

Is a new weight-loss drug making people fall out of love? | Weight-loss drugs | The Guardian

Some people using retatrutide, which is not yet approved, are reporting ‘emotional flattening’, but experts point to a more complex picture

theguardian.com →

A woman prepares for a subcutaneous self-injection. Retatrutide, which is in clinical trials, targets three appetite-related hormones. Photograph: Jon Challicom/Getty Images A woman prepares for a subcutaneous self-injection. Retatrutide, which is in clinical trials, targets three appetite-related hormones. Photograph: Jon Challicom/Getty Images What are peptides, are they safe and is there evidence to back up the hype? A recent TikTok video shows a man in a black baseball cap, with text over the video stating: “strange effects of Reta” and “ruining relationships”. He is referring to retatrutide, an experimental weight-loss drug that targets three appetite-related hormones. It is still in clinical trials but has generated such interest that some users are already sourcing it illegally online before approval. The “weird theory going around”, the TikTok poster says, is that the drug can “make you fall out of love”. Below the video, the comments fill with accounts of what users describe as emotional flattening. One person says the drug “stopped food craving and lusting as well”, another says they have “severe anhedonia [the inability to experience joy or pleasure]”, and a third says retatrutide made them feel “unbothered by 99% of everything”. While retatrutide is the newest and most potent, reports of “emotional flatness” have also surfaced among users of approved GLP-1 drugs, such as Mounjaro. A recent case report suggests that such medications can influence brain regions involved in emotional regulation and potentially trigger or worsen severe depressive symptoms. On whether such drugs could alter love, emotion or social bonds, Kenny was more cautious, saying he could not comment directly from a neurobiological perspective. But he added that it would not surprise him if medications so closely tied to the body’s energy systems also shaped human emotions and social interactions. “A lot of animal behaviour is influenced by energetics and energy availability, all the things tied to survival,” he said. Because GLP-1 is intimately linked to energy status, he said, it was plausible that shifting those signals could also modify behaviour. What are peptides, are they safe and is there evidence to back up the hype? In animals, for example, Kenny said territoriality often increased when food was scarce, suggesting energy balance can shape the nature of social interactions. “GLP-1 is also linked to how the brain processes reward and pleasurable stimuli,” he said. These drugs have been affecting libido, as Dr Naveed Asif, a GP from London General Practice, explained: “From a physical perspective, GLP-1 medications affect smooth muscle activity, which can influence arousability and orgasm due to changes in blood flow to the genital area. “Chemically, the effects may vary among different patient groups, but there’s also a dopaminergic component: dopamine, a hormone released in the brain in response to stimuli, may decrease when using these peptides. This creates challenges related to desire and sexual attraction, potentially impacting overall sexual function.” He adds: “Oestrogen is a key sex hormone, so taking GLP-1s might disrupt its balance, which can lead to emotional disturbances. This issue appears to be more pronounced in women using these peptides. “I have observed that many women experience significant side-effects that lead them to discontinue the medication. Some patients reported worsening mental health, including increased depression and anxiety, which likely affects sexual function as a secondary consequence.” Dr Sophie Dix, from the online pharmacy MedExpress, said the “leap from ‘reduced food cravings’ to ‘unable to fall in love’ is where the science currently doesn’t follow. Romantic attachment is a much more complex neurobiological process than a single reward pathway.” Dix noted that because GLPs affect the reward areas of the brain, they are believed to reduce compulsive behaviours. “This could indeed impl

Excerpt from a page describing this subject · 8,834 chars · not written by Vinony

Wikidata facts

Instance of
agonist
Show 3 more facts
Sources (1)

via Wikidata · CC0

~3 min read

Encyclopedic overview

5 sections
Contents
  • Clinical trials
  • Chemistry
  • Research
  • See also
  • References

Retatrutide (LY-3437943) is an experimental drug for obesity developed by the American pharmaceutical company Eli Lilly and Company. It is a triple glucagon hormone receptor agonist (GLP-1, GIP, and GCGR receptors).

== Clinical trials == Retatrutide has been studied in a phase 2 trial involving adults without diabetes but with obesity or preobesity (overweight). Retatrutide is also being evaluated in phase 3 clinical trials. A substudy in adults with type 2 diabetes reported differences in total body fat mass between study groups at 36 weeks.

Excerpted from Wikipedia’s “retatrutide” article, available under the CC BY-SA 4.0 licence.

Available in 8 languages

via Wikidata sitelinks · CC0